Conflicting trends confound the pharmaceutical industry. The productivity of pharmaceutical innovation has declined in recent years. At the same time, the cohort of large companies who are the leading engines of pharmaceutical R&D has become increasingly concentrated. The concurrent presence of these trends is not sufficient to determine causation. In response to lagging innovation prospects, s...

Regarding to rapidly changing and highly competitive business environment it will become increasingly important for organizations to measure their performances appropriately. With respect to special characteristics of pharmaceutical industry and lack of reported performance measurement, this study tries to design an integrated performance measurement model for pharmaceutical companies. For gene...

Indian pharmaceutical industry has carved out a unique place on the global map, not only as a manufacturer of generic drugs but also of new formulations, with growing emphasis on research and development and new drug discovery. The present paper examines the short-run abnormal returns to India based mergers and acquisitions focusing on the pharmaceutical industry during 2001-2007 by using event...

The purpose of this study is to clarify the benefit and loss for the pharmaceutical companies when they adopt introducing pharmacogenomics in their clinical trials (in the following description, clinical trials by using pharmacogenomics is called "pgx clinical trial"), that is, when they use genetic information in their clinical trials. Particularly, the benefit for the pharmaceutical companies...

Patents on many blockbuster drugs will expire in the near future, opening up the doorways for generic production. Brandname drug companies lose an estimated half of their U.S. sales during the first six months of generic production alone. In an effort to forestall large sales declines, some brand-name pharmaceutical companies are scrambling to delay generic production. One measure brand-name ph...

BACKGROUND Most European health care systems are suffering from the impact of demographic change. In short, aging of society is leading to higher costs of treatment per capita, while reproduction rates below 2.1 children per woman lead to a reduced number of younger people to provide for the necessary contributions into the health insurance system.This research paper addresses the questions wha...

Having validated analysis methods for medicinal ingredients is attractive for pharmaceutical companies. When a new molecule is introduced to the market, there is not any pharmacopeial analysis method for that. After publishing official methods, correlation between validated in-house methods and the official one could stablish the value of the in-house method. Sitagliptin phosphate is a new anti...

This article discusses tbe Medical Documentation Service’” (MDS) of the Institute for Scientific Information@ and the information services it provides m assist biomedical and pharmaceutical companies in managing and controlling publisbed product literature. MDS works individtmfly with each client to establish criteria for regularly updating in-house databases and other product literature files ...